UK novel RNA therapeutics specialist Silence Therapeutics (AIM: SLN) has issued a claim in the UK High Courts of Justice against US biotech firm Alnylam Pharmaceuticals (Nasdaq: ALNY).
The claim asks the court to determine whether Silence is entitled to supplementary protection certificates (SPCs) on several late-stage Alnylam products.
These include the hATTR amyloidosis candidate patisiran, investigational hemophilia treatment fitusiran and givosiran, being investigated for the prophylaxis of attacks in patients with acute hepatic porphyria.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze